Table 1.

Characteristics of 90 patients with locally advanced breast cancer subjected to neoadjuvant chemotherapy with a combination of epirubicin and docetaxel.

Age [mean (SD)]	49 (11.5)
Menopausal status [n (%)]
Pre	40 (44.4%)
Post	50 (55.6%)
Clinical stage [n (%)]
II	44 (48.9%)
III	46 (51.1%)
Histology [n (%)]
Ductal	80 (88.9%)
Others	10 (11.1%)
Grade [n (%)]
1	16 (17.8%)
2	52 (57.8%)
3	22 (24.4%)
ER positive [n (%)]	57 (63.3%)
PgR positive [n (%)]	39 (43.3%)
HER2 positive [n (%)]	25 (27.7%)
Objective response [n (%)]	72 (80%)
Breast-conserving surgery rate [n (%)]	47 (52.8%)
pCR [n (%)]	11 (12.2%)
Negative ALN [n (%)]	38 (42%)

ER, estrogen receptor; PgR, progesterone receptor; pCR, complete pathological response; ALN, axillary lymph node.